Therapeutic effects of direct renin inhibitor aliskiren added to AT1 receptor blocker in hypertensive patients with chronic kidney disease.
Phase 4
- Conditions
- Hypertension Chronic kidney disease
- Registration Number
- JPRN-UMIN000002546
- Lead Sponsor
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1. Dialysis patients 2. Patients with history of angioedema 3. Patients on apheresis therapy 4. Patients taking cyclosporin 5. History of hypersensitivity to benazepril and/or aliskiren 6. Pregnant women and/or women who are suspect of pregnancy 7. Patients judged as inappropriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Blood pressure (clinical BP, ABPM) 2. Renal function (s-Cr, eGFR, urinary protein/albumin excretion)
- Secondary Outcome Measures
Name Time Method 1. Glucose metabolism (FBS, HbA1C, IRI, HOMA-IR) 2. Lipid metabolism (TCHO, LDLC, HDLC, TG) 3. Sympathetic nerve activity, renin-angiotensin system (PRA, PAC, catecholamine, urinary AGT) 4. Oxidative stress (urinary L-FABP, serum pentosidine) 5. Cardiovascular function (BNP, UCG, PWV, central blood pressure) 6. Adverse events